Wuhan Cost Of Revenue vs Selling General Administrative Analysis

300871 Stock

11.40 0.01 0.09%

Wuhan Hvsen financial indicator trend analysis is more than just analyzing Wuhan Hvsen Biotechnology current accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Wuhan Hvsen Biotechnology is a good investment. Please check the relationship between Wuhan Hvsen Cost Of Revenue and its Selling General Administrative accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Wuhan Hvsen Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

Cost Of Revenue vs Selling General Administrative

Cost Of Revenue vs Selling General Administrative Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Wuhan Hvsen Biotechnology Cost Of Revenue account and Selling General Administrative. At this time, the significance of the direction appears to have strong relationship.

The correlation between Wuhan Hvsen's Cost Of Revenue and Selling General Administrative is 0.79. Overlapping area represents the amount of variation of Cost Of Revenue that can explain the historical movement of Selling General Administrative in the same time period over historical financial statements of Wuhan Hvsen Biotechnology, assuming nothing else is changed. The correlation between historical values of Wuhan Hvsen's Cost Of Revenue and Selling General Administrative is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cost Of Revenue of Wuhan Hvsen Biotechnology are associated (or correlated) with its Selling General Administrative. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Selling General Administrative has no effect on the direction of Cost Of Revenue i.e., Wuhan Hvsen's Cost Of Revenue and Selling General Administrative go up and down completely randomly.

Correlation Coefficient

0.79

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Cost Of Revenue

Cost of Revenue is found on Wuhan Hvsen Biotechnology income statement and represents the costs associated with goods and services Wuhan Hvsen provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Selling General Administrative

Most indicators from Wuhan Hvsen's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Wuhan Hvsen Biotechnology current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Wuhan Hvsen Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

The current year's Tax Provision is expected to grow to about (4.1 M). In addition to that, Selling General Administrative is expected to decline to about 52.6 M

	2023	2024 (projected)
Minority Interest	17.0K	14.4K
Income Tax Expense	4.6M	4.4M

Minority Interest Income Tax Expense

Wuhan Hvsen fundamental ratios Correlations

	Other Current Liab	Total Current Liabilities	Other Liab	Net Tangible Assets	Retained Earnings	Accounts Payable	Other Assets	Net Receivables	Inventory	Other Current Assets	Other Stockholder Equity	Deferred Long Term Liab	Total Current Assets	Common Stock	Property Plant Equipment	Total Assets	Total Stockholder Equity	Cash	Non Current Assets Total	Non Currrent Assets Other	Long Term Debt	Common Stock Shares Outstanding	Non Current Liabilities Total	Total Liab	Net Invested Capital	Non Current Liabilities Other
Other Current Liab		0.32	0.04	0.24	0.5	0.32	0.32	0.38	0.36	0.44	0.33	0.06	0.49	0.3	0.04	0.38	0.44	0.57	0.28	0.43	0.44	0.36	0.14	0.3	0.4	0.73
Total Current Liabilities	0.32		0.91	0.89	0.89	1.0	0.68	0.98	0.94	-0.02	0.57	-0.34	0.9	0.97	0.9	0.97	0.92	0.65	1.0	0.22	0.91	0.89	0.9	0.99	0.96	0.43
Other Liab	0.04	0.91		0.94	0.82	0.9	0.64	0.89	0.86	-0.05	0.53	-0.31	0.81	0.86	0.99	0.9	0.85	0.59	0.92	0.15	0.82	0.88	0.95	0.9	0.89	0.29
Net Tangible Assets	0.24	0.89	0.94		0.92	0.89	0.78	0.93	0.93	0.15	0.61	-0.34	0.94	0.89	0.93	0.95	0.96	0.77	0.9	0.4	0.94	0.99	0.91	0.89	0.95	0.58
Retained Earnings	0.5	0.89	0.82	0.92		0.9	0.83	0.96	0.94	0.23	0.78	-0.34	0.97	0.88	0.8	0.95	0.96	0.82	0.88	0.53	0.94	0.95	0.81	0.87	0.95	0.7
Accounts Payable	0.32	1.0	0.9	0.89	0.9		0.67	0.98	0.95	-0.04	0.56	-0.37	0.9	0.97	0.9	0.97	0.92	0.66	1.0	0.22	0.91	0.89	0.9	0.99	0.96	0.44
Other Assets	0.32	0.68	0.64	0.78	0.83	0.67		0.78	0.69	0.47	0.7	-0.4	0.8	0.62	0.57	0.73	0.82	0.53	0.64	0.84	0.84	0.84	0.49	0.59	0.74	0.74
Net Receivables	0.38	0.98	0.89	0.93	0.96	0.98	0.78		0.97	0.08	0.68	-0.38	0.96	0.95	0.88	0.99	0.97	0.73	0.97	0.38	0.95	0.95	0.88	0.96	0.98	0.56
Inventory	0.36	0.94	0.86	0.93	0.94	0.95	0.69	0.97		0.02	0.65	-0.36	0.97	0.98	0.87	0.98	0.96	0.84	0.95	0.3	0.94	0.93	0.91	0.96	0.99	0.57
Other Current Assets	0.44	-0.02	-0.05	0.15	0.23	-0.04	0.47	0.08	0.02		0.41	0.51	0.2	-0.05	-0.09	0.06	0.2	0.11	-0.07	0.66	0.25	0.23	-0.16	-0.1	0.07	0.55
Other Stockholder Equity	0.33	0.57	0.53	0.61	0.78	0.56	0.7	0.68	0.65	0.41		0.01	0.65	0.54	0.49	0.6	0.63	0.53	0.54	0.52	0.6	0.62	0.48	0.52	0.6	0.47
Deferred Long Term Liab	0.06	-0.34	-0.31	-0.34	-0.34	-0.37	-0.4	-0.38	-0.36	0.51	0.01		-0.36	-0.35	-0.28	-0.37	-0.38	-0.29	-0.35	-0.28	-0.36	-0.36	-0.28	-0.34	-0.37	-0.26
Total Current Assets	0.49	0.9	0.81	0.94	0.97	0.9	0.8	0.96	0.97	0.2	0.65	-0.36		0.93	0.81	0.97	0.99	0.87	0.9	0.49	0.98	0.97	0.83	0.9	0.98	0.75
Common Stock	0.3	0.97	0.86	0.89	0.88	0.97	0.62	0.95	0.98	-0.05	0.54	-0.35	0.93		0.88	0.98	0.93	0.75	0.98	0.19	0.92	0.89	0.91	0.98	0.97	0.48
Property Plant Equipment	0.04	0.9	0.99	0.93	0.8	0.9	0.57	0.88	0.87	-0.09	0.49	-0.28	0.81	0.88		0.9	0.84	0.61	0.92	0.07	0.81	0.87	0.98	0.92	0.89	0.26
Total Assets	0.38	0.97	0.9	0.95	0.95	0.97	0.73	0.99	0.98	0.06	0.6	-0.37	0.97	0.98	0.9		0.98	0.79	0.98	0.33	0.97	0.96	0.91	0.97	1.0	0.59
Total Stockholder Equity	0.44	0.92	0.85	0.96	0.96	0.92	0.82	0.97	0.96	0.2	0.63	-0.38	0.99	0.93	0.84	0.98		0.83	0.92	0.49	0.99	0.99	0.85	0.91	0.99	0.72
Cash	0.57	0.65	0.59	0.77	0.82	0.66	0.53	0.73	0.84	0.11	0.53	-0.29	0.87	0.75	0.61	0.79	0.83		0.67	0.36	0.78	0.79	0.73	0.71	0.81	0.75
Non Current Assets Total	0.28	1.0	0.92	0.9	0.88	1.0	0.64	0.97	0.95	-0.07	0.54	-0.35	0.9	0.98	0.92	0.98	0.92	0.67		0.16	0.9	0.89	0.92	1.0	0.97	0.41
Non Currrent Assets Other	0.43	0.22	0.15	0.4	0.53	0.22	0.84	0.38	0.3	0.66	0.52	-0.28	0.49	0.19	0.07	0.33	0.49	0.36	0.16		0.53	0.51	0.01	0.12	0.35	0.82
Long Term Debt	0.44	0.91	0.82	0.94	0.94	0.91	0.84	0.95	0.94	0.25	0.6	-0.36	0.98	0.92	0.81	0.97	0.99	0.78	0.9	0.53		0.98	0.8	0.89	0.97	0.74
Common Stock Shares Outstanding	0.36	0.89	0.88	0.99	0.95	0.89	0.84	0.95	0.93	0.23	0.62	-0.36	0.97	0.89	0.87	0.96	0.99	0.79	0.89	0.51	0.98		0.85	0.88	0.96	0.69
Non Current Liabilities Total	0.14	0.9	0.95	0.91	0.81	0.9	0.49	0.88	0.91	-0.16	0.48	-0.28	0.83	0.91	0.98	0.91	0.85	0.73	0.92	0.01	0.8	0.85		0.94	0.91	0.3
Total Liab	0.3	0.99	0.9	0.89	0.87	0.99	0.59	0.96	0.96	-0.1	0.52	-0.34	0.9	0.98	0.92	0.97	0.91	0.71	1.0	0.12	0.89	0.88	0.94		0.96	0.4
Net Invested Capital	0.4	0.96	0.89	0.95	0.95	0.96	0.74	0.98	0.99	0.07	0.6	-0.37	0.98	0.97	0.89	1.0	0.99	0.81	0.97	0.35	0.97	0.96	0.91	0.96		0.61
Non Current Liabilities Other	0.73	0.43	0.29	0.58	0.7	0.44	0.74	0.56	0.57	0.55	0.47	-0.26	0.75	0.48	0.26	0.59	0.72	0.75	0.41	0.82	0.74	0.69	0.3	0.4	0.61

Click cells to compare fundamentals

Wuhan Hvsen Account Relationship Matchups

Wuhan Hvsen fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Other Current Liab	22.2M	45.0M	57.9M	61.5M	3.8M	3.7M
Total Current Liabilities	203.8M	338.7M	503.3M	804.9M	781.1M	410.7M
Other Liab	24.3M	28.0M	45.0M	72.4M	83.3M	87.4M
Net Tangible Assets	280.1M	1.3B	1.5B	1.4B	1.6B	1.7B
Retained Earnings	191.6M	341.8M	429.3M	427.1M	341.9M	271.4M
Accounts Payable	121.1M	194.4M	311.3M	489.7M	472.5M	240.9M
Other Assets	26.0M	67.0M	25.9M	32.7M	37.6M	26.7M
Net Receivables	107.0M	201.7M	259.5M	338.0M	318.5M	190.8M
Inventory	72.4M	127.3M	231.6M	199.0M	228.7M	144.0M
Other Current Assets	8.7M	25.0M	9.4M	8.6M	5.3M	9.1M
Total Current Assets	292.5M	1.2B	1.6B	1.4B	1.3B	863.0M
Property Plant Equipment	233.3M	412.3M	1.0B	1.5B	1.7B	1.8B
Total Assets	650.1M	1.8B	2.7B	3.0B	3.0B	1.9B
Total Stockholder Equity	378.3M	1.4B	1.6B	1.5B	1.5B	1.1B
Cash	104.5M	345.3M	1.1B	424.0M	293.6M	375.3M
Non Current Assets Total	357.5M	575.1M	1.1B	1.6B	1.7B	908.3M
Non Currrent Assets Other	15.5M	56.7M	15.5M	7.5M	3.6M	3.4M
Non Current Liabilities Total	68.0M	34.4M	619.5M	642.8M	685.1M	719.4M
Total Liab	271.8M	373.1M	1.1B	1.4B	1.5B	777.0M
Net Invested Capital	441.0M	1.4B	2.3B	2.3B	2.4B	1.5B
Net Working Capital	88.8M	838.5M	1.1B	546.5M	484.9M	510.8M
Intangible Assets	98.2M	95.8M	110.1M	106.9M	104.2M	101.2M
Short Long Term Debt	29M	63M	100M	220.1M	240.3M	124.2M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Other Information on Investing in Wuhan Stock

Balance Sheet is a snapshot of the financial position of Wuhan Hvsen Biotechnology at a specified time, usually calculated after every quarter, six months, or one year. Wuhan Hvsen Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Wuhan Hvsen and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Wuhan currently owns. An asset can also be divided into two categories, current and non-current.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Wuhan Cost Of Revenue vs Selling General Administrative Analysis

Cost Of Revenue vs Selling General Administrative

Cost Of Revenue vs Selling General Administrative Correlation Analysis

Correlation Coefficient

Cost Of Revenue

Selling General Administrative

Wuhan Hvsen fundamental ratios Correlations

Wuhan Hvsen Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Wuhan Hvsen fundamental ratios Accounts

Also Currently Popular

Other Information on Investing in Wuhan Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Accounts Payable	+ 1.0	Total Current Liabilities
Non Current Assets Total	+ 1.0	Total Current Liabilities
Non Current Assets Total	+ 1.0	Accounts Payable
Net Invested Capital	+ 1.0	Total Assets
Total Liab	+ 1.0	Non Current Assets Total
Total Liab	+ 0.99	Total Current Liabilities

Deferred Long Term Liab	- 0.4	Other Assets
Total Stockholder Equity	- 0.38	Deferred Long Term Liab
Deferred Long Term Liab	- 0.38	Net Receivables
Net Invested Capital	- 0.37	Deferred Long Term Liab
Total Assets	- 0.37	Deferred Long Term Liab
Deferred Long Term Liab	- 0.37	Accounts Payable